You're up, Europe

Houston SaaS company expands in Europe following acquisition

With its new German office, Houston-based DiCentral looks to grow into other European markets, such as France, Italy, and Spain. Pexels

After slowly expanding worldwide for years, a Houston-based software-as-a-service company finally has a firm footing in Europe following its acquisition of a German company.

In December, DiCentral closed its deal with a Munich-based supply chain company named Compello Germany. With that acquisition, DiCentral Europe was born. Steve Scala, executive vice president of corporate development, says the deal was made possible after the company raised $15 million from Kanye Anderson Capital Advisors LP in 2016.

"We have a large supply chain network over Asia and North America, which gave us great coverage for our clients. In Europe, however, we're dealing with different supply chains," Scala says. "We had few people on the ground in Europe even though we have clients based there as well as clients elsewhere who conduct business there. We saw the need to fill that gap."

The new German office opens doors for the company to enter other European markets, and Scala says the company is looking into France, Italy, and Spain.

Currently, DiCentral's largest offices are in Houston and Ho Chi Minh City where they employ 150 and 300 people respectively. The company, which was founded in 2000 by Chairman and CEO Thuy Mai, has about 600 employees in total, and focuses on bonding buyers and suppliers, so both sides can optimize both the physical and digital supply chain.

DiCentral offers cloud-based electronic data interchange and supply chain solutions to its clients. By using DiCentral's propriety software, its clients, which include retailers, original equipment manufacturers, suppliers and more across many industry verticals, can find solutions tailored to their business.

"Global supply chains quickly can become very complex, especially when you add web purchases or individual orders from retailers that are sent from the manufacturers but made to look like they were sent from the retailer," Scala explains.

DiCentral allows businesses to improve their visibility of the supply chain by automating fulfillments, shipping and receiving processes.

"The end result for clients, whether they are a manufacturer, retailer or a third-party involved in distribution, using our software is improving the efficiency of supply chain," Scala continues. "With our solutions, clients can ramp up their operations even when navigating incredibly complex supply chains."

As DiCentral plans its continued European expansion, the company is facing various challenges from training its new 35 employees in Munich to potential logistical and regulatory issues.

"Our primary focus in 2019 is integrating the German operations with DiCentral. There are a lot of privacy challenges in Europe with GDPR, which means we need to be smart and cautious with how to deploy data centers because of stricter data privacy rules," Scala says.

Despite the challenges, Scala expects the new acquisition to lead to large growth for the company.

"I'm excited for the future. We closed on some great business contracts last year, however, the way our business works, we don't make money until there are transactions taking place across our network," Scala says.

It can take months to fully integrate clients into the DiCentral network, but Scala looks forward to the new revenue source. New contracts with large companies will allow DiCentral to continue fueling its global growth. The company continues to grow and hire, both abroad and locally, for various positions in sales, customer support, product management and marketing.

While the business continues to grow with an eye on new market sectors and areas for expansion, the DiCentral global headquarters are still located right by NASA. As a company founded in Texas, many of its original client base is based within the state.

"Texas has been a great location for us. We have data centers here in Texas, our headquarters are in Houston, so the original infrastructure of the company is all in Texas," says Scala.


Steve Scala joined DiCentral in 2014 to focus on growing the company worldwide. Courtesy of DiCentral

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News